A team led by scientists at Harvard Medical School, Massachusetts General Hospital, and the Broad Institute of MIT and ...

The FDA has approved Bosaya and Aukelso, biosimilars to Prolia (denosumab) and Xgeva (denosumab), respectively.

Iberdomide combined with standard therapies showed a statistically significant improvement in minimal residual disease (MRD) ...

The global rise in obesity is staggering. Obesity has doubled in over 70 nations within a span of a mere four decades.

As September ushers in Cancer Awareness Month, it also brings with it stories of resilience, breakthroughs, and hope. In Pune ...

Decades of slow-moving research, along with broader failures of the healthcare system, have left millions of people in daily ...

Major advancements in biosimilars emerge in Europe and Middle East and North Africa (MENA) region, enhancing patient access ...

Before a chain of amino acids can become an active and useful protein, it must be processed and folded into the appropriate ...

Researchers at Duke University have shown that blocking an enzyme involved in iron regulation not only kills multiple myeloma cancer cells, but also increases the effectiveness of current therapies ...

Bernstein 2nd Annual Global Healthcare Conference September 24, 2025 1:10 PM EDTCompany ParticipantsTom Cavanaugh - ...

Researchers from Mass General Brigham and the Broad Institute of MIT and Harvard have identified genetic modifications that ...

Bristol Myers Squibb (BMY) announced on Tuesday that a late-stage study evaluating Iberdomide in patients with relapsed or ...